Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Kwong AD, Zeuzem S. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C . Hepatology. 2007. 46(3). . Find at Google Scholar.
Qiu P, Sanfiorenzo V, Curry S, Guo Z, Liu S, Skelton A, Xia E, Cullen C, Ralston R, Greene J, Tong X. Identification of HCV protease inhibitor resistance mutations by selection pressure-based method. . Nucleic Acids Res. . 2009. 37(10). e74. Find at Google Scholar.
Flint M, Mullen S, Deatly AM, Chen W, Miller LZ, Ralston R, Broom C, Emini EA, Howe AY. . Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and. Antimicrob Agents Chemother. . 2009. 53(2). 401-411. Find at Google Scholar.
Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, Dondero E, Kwong A. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely. J Virol. . 2013. 87(3). 1544-1553. Find at Google Scholar.
Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravend. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and rib. Lancet. 2010. 376(9742). 705-716. Find at Google Scholar.